MetLife (MET) › Analysis

MetLife (MET) stock analysis, November 3, 2026: Uptrend intact into earnings, breakout above $103.57 unconfirmed

Published November 3, 2026 · MET chart, levels and live analysis

MetLife (MET) trades at about $100.55 the day before its November 4, 2026 earnings report, 2.9% below its October 22 peak of $103.57. The balance of evidence leans positive, with high conviction. The stock sits above its 40-week average, leads both the S&P 500 and the financial sector over 50 days, and its daily trend runs with the weekly one. The breakout above $103.57 that followed the peak has not yet been confirmed.

Why it matters

No company-specific event explains this week's price action. The only headline tagged to MET, Bloomberg, is about CNP Assurances saying it remains open to Latin American acquisitions, which concerns a different insurer. The stock fell 0.4% today and has given back 2.9% from its peak, but volume is running 58% below its 20-day average. That looks like a quiet pause, not forced selling. The real event is tomorrow's earnings.

Much of the good news is already in the price. MET is up 27.4% year to date against 10.6% for the S&P 500 (SPY), and 6.5% over the past month while SPY fell 2.0%. A stock that has outrun the market by that margin enters earnings with expectations built in.

Over the last five days the market was the headwind and the sector was the tailwind. SPY lost 2.0% and the financial sector ETF (XLF) gained 2.2%. MET rose 0.6%, so it held up well in a falling market but trailed its sector by 1.7 points. The stock did not lead this week. It rode a sector bid that was stronger than its own.

The argument about MET centers on whether the October rally was a real breakout. Seeking Alpha took the positive side on October 22, pointing to a 32% year-to-date gain, a technical breakout and upside into earnings. Zacks, via NASDAQ, named MET among five insurers expected to beat third-quarter estimates, citing pricing and policy retention. The cautious side appears in the price. The stock has since slipped back from that high on thin volume, so the breakout has not been confirmed, and a quarter of expected beats leaves little room for an ordinary report.

Valuation leaves moderate room. Sixteen analysts rate the stock a buy, with a mean price target of $107.63, which is 6.6% above the current price. Targets run from $84 to $119. The low end sits below the 200-day average of $85.92, so the spread is wide, but the center of it is above the market.

What the evidence says

The long-term thesis is intact. The price is above its 40-week average, the 50-day average ($97.90) is well above the 200-day ($85.92), and the stock is 48.5% above its 52-week low of $67.70. This is a mature uptrend that is consolidating just under its high, not one that is rolling over.

For the next two to six weeks the balance of evidence leans positive, and conviction is high at 3 of 4 points. Three things support it: the daily trend runs with the weekly uptrend, the stock leads the S&P 500 over 50 days (+4.5%), and it leads XLF over 50 days (+0.6%). The lead over the sector is thin, but it is a lead. Against that, the pullback has not been bought with volume, momentum has cooled to a neutral RSI of 52.6, and the stock lagged its sector this week. The price is also only about $0.55 above the $100 level that frames the structure, with a binary earnings report tomorrow. That is why conviction is high rather than absolute. None of it breaks the trend or the relative strength, so it does not tip the balance.

Levels that matter

The structure holds above $100, a round number and the first level the price would have to give up. A break below it is the first crack. Beneath it sit a swing zone at $98.38 and the 50-day average at $97.90. A weekly close below $97.90 is where the uptrend would end. That is the average the stock has respected through the climb.

The breakout level is a daily close above $103.57, the 52-week high, on volume above its 20-day average. From there the math uses a stop at $99.47, which is $100 less a quarter of the 14-day ATR of $2.10. The first target is $125, giving 5.2 to 1. The second is $150, giving 11.3 to 1. Both clear the 3 to 1 threshold that makes a breakout worth the risk. Both are round numbers, not measured moves, and $125 is above the highest analyst target of $119.

What would change the picture

A weekly close below $97.90, the 50-day average, would change the picture. The non-price fact that would do it is an earnings report, or guidance with it, that falls short of the consensus estimates that analysts and Zacks expect MET to beat. That would take away the catalyst the breakout case depends on.

What to watch

Get a message when the MET picture changes — the agent team watches the levels and the news for you.Create a free account

More MET analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.